Effect of Aripiprazole on Smoking Rate in Male Bipolar Mood Disorders I
Purpose: Significant impairment in functioning of patients with mental disorders is created. Bipolar disorder is a common and debilitating mental illness that ranks the fifth for the burden of disease among all patients. It is hard to treat the disorder and stabilize patient’s mood for a long-term due to lack of patient compliance, multiple recurrences and severity of the disease. The most common, costly and the deadliest addiction would belong to nicotine which is often neglected and involved people with bipolar disorder. Smoking and consequently mortality rate in psychiatric patients is higher than the population.
Methods: The interventional research studied all patients with Bipolar Disorder type I is. Forty randomly selected patients were divided into two groups: Aripiprazole and placebo. The samples were examined two times; at the baseline and after 6 weeks, with Young Mania Rating Scale, and Fagerstrom Test for nicotine dependence. Data were analyzed using the software package SPSS 18 and p-value <0.05.
Results: Aripiprazole Group showed statistically significant difference in reduction in nicotine use between phases of before and after treatment, but it was not true in the placebo group. The intervention group decreased smoking significantly after 6 weeks of treatment, in contrast to the placebo group.
Conclusion: Aripiprazole reduces smoking in patients with Bipolar Disorder type I.
Strain EC, Anthony JC(2009). Substance – Related Disorders. In: Sadock BJ, Sadock VA, Ruiz P: Comprehensive textbook of Psychiatry, 9th ed. Lippincott Williams& Wilkson, New york, 1237-67.
Hughes JR(2009). Sabstance – Related Disordera. In: Sadock BJ, Sadock VA, Ruiz P: Comprehensive textbook of Psychiatry, 9th ed. Lippincott Williams& Wilkson, New york,1353-59.
Lyon ER. 1999. A Review of the Effects of Nicotine on Schizophrenia and Antipsychotic Medications. [on line] availble from: http://www.ncbi.nlm.nih.gov/pubmed/10506305.
Mills EJ, Wu P, Spurden D, Ebbert Jo, Wilson K. 2009. Efficacy of pharmacotherapies for short – term Smoking Abstinence. [on line] available from: http://www.harmreductionyournal.com/content/6/1/25.
Cahil K, Stead LF, Lancaster T. 2011. Nicotine Receptor partial Agonists for Smoking Cassation. [on line] availble from: http://www.ncbi.nlm.nih.gov/pubmed/17253581.
Ramaswamy S, Bhabita SC. Aripiprazole therapy for Nicotine dapendence. Prim Care Companion J Clin Psychiatry. 2006; 8(1): 47–49.
Arabiazar B, Acebo IG, Iorca JL.2008. Decrease in tobacco Consumption After Treatmente and Apripiprazolle. J Med Case Rep. 2008 Jun 11;2:198.
Marder SR, Hurford IM, Van Kammen DP(2009). Biological therapies. In: Sadock BJ, Sasock VA, Ruiz P: Comprehensive textbook of Psychiatry, 9th ed. Lippincott Williams& Wilkson, New york, 3206-40.
McIntyre R, Yoon J, Jerrell JM, Liauw SS.Aripiprazole for the maintenance treatment of bipolar disorder: a review of available evidence. Neuropsychiatric Disease and Treatment 2011;7(1):319-323.
Tsai AC, Rosenlicht NZ, Jureidini JN, Parry PI, Spielmans GI, et al.Aripiprazole in the Maintenance Treatment of Bipolar Disorder: A Critical Review of the Evidence and Its Dissemination into the Scientific Literature. PLoS Med 2011;8(5): e1000434. doi:10.1371/journal.pmed.1000434.
Fountoulakis K N,Vieta E. Efficacy and safety of aripiprazole in the treatment of bipolar disorder: a systematic review.Annals of General Psychiatry2009;8:16.DOI: 10.1186/1744-859X-8-16.
Heatherton TF, Kozlowski LT, Frecker RC, et al. The Fagerström Test for Nicotine Dependence: a revision of the Fagerström Tolerance Questionnaire. British Journal of Addiction 1991; 86: 1119-27.
Fagerström KO, Schneider N. Measuring nicotine dependence: A review of the Fagerström Tolerance Questionnaire. J Behav Med 1989; 12: 159–82.
Heydari GR, Sharifi Milani H, Hosseini M, et al. Tobacco Dependency evaluation with Fagerstrom Test among the Entrants of Smoking Cessation Clinic, Tanaffos 2007; 6: 4752.
Heydari Gh, Sharifi Milani H, Hosseini M, et al. The effect of Training and Behavioral Therapy Recommendations on smoking Cessation (A Report of the first "Smoking Cessation Clinic" in Iran). Tanaffos 2003; 2: 39-44.
American Psychiatric Association. (2013). Diagnostic and statistical manual of mental disorders. 5th ed. Arlington, VA: American Psychiatric Publishing.
Fajutrao L, Locklear J, Priaulx J, Heyes A. (2009). A systematic review of the evidence of the burden of bipolar disorder in Europe. Clinical Practice and Epidemiology in Mental Health. 5:3
Vieta E,Sanchez-Moreno J. (2008). Acute and long-term treatment of mania. Dialogues in Clinical Neuroscience. 10, 2.
3) Hilty D, Hilty L, Lim D, Kelly D. (2006). A Review of Bipolar Disorder in Adults. Psychiatry. 43-55
American Psychiatric Association (APA). (2000). Diagnostic and statistical manual of mental disorders. Text revision. 4th ed. Washington D.C: American psychiatric association press. 167-208.
Nystazaki M, Tsapakis EM, Hadjulis M, Alevizopoulos G. (2014) Validation of the Glasgow Antipsychotic Side-Effect Scale (GASS) in Greece. J Psychol Clin Psychiatry. 1(4): 00024. DOI: 10.15406/jpcpy.2014.01.00024
Heffner J L, Strawn J R, DelBello M P, Strakowski S M, Anthenelli R M.The Co-occurrence of Cigarette Smoking and Bipolar Disorder: Phenomenology and Treatment Considerations. Bipolar Disord. 2011; 13(0): 439–453.
Merikangas K R, Jin R, He J, Kessler R C, Lee S Et al. Prevalence and Correlates of Bipolar Spectrum Disorder in the World Mental Health Survey Initiative. Arch Gen Psychiatry. 2011; 68(3): 241–251.
Matthews A M, Wilson V B, Mitchell S H. the role of antipsychotics in smoking and smoking cessation. review article cns drugs 2011; 25 (4): 299-315
Hughes JR. Tobacco withdrawal in self-quitters. J Consult Clin Psychol. 1992;60:689–697.
Zamir S M, Javdani H, Massoudifar A, Naghdipour M, Mehrnami A. The effect of aripiprazole on nicotine dependency in patients under methadone maintenance therapy. European Psychiatry 2017;14(Supplement):S398
Asghar Arfaiea , Hossein Javdanib , Ayyoub Malekc , Mostafa Farahbakhshd. Effect of Aripiprazole on Smoking Rate in Schizophrenic Patients. J Clin Res Gov, 2015, 4(1): 1-6
Ebrahimi A, Kheyr Z, Nasiri H, Barnamanesh AR. Reliability, Validity, Factor and Discrimination Power Analysis of Young Mania Rating Scale among Unipolar, Bipolar Depression and Healthy People. Jundishapur Sci Med J 2017;16(3):333-344.
27. Liu Y, Sun HQ, Bao YP, Li SX, Beveridge TJ, Di XL, Yang FD, Lu L. Subjective, cognitive/psychomotor, and physiological effects of aripiprazole in Chinese light and heavy smokers. Drug and Alcohol Dependence. 2009,101 (1-2): 42-52.
28. Kim SH, Han DH, Joo SY. The effect of dopamine partial agonists on the nicotine dependency in patients with schizophrenia. Human Psychopharmacology.2009, 25 (2):187-90.